SCHEMBL487498

SCHEMBL487498

CNc1ccc(N2CCOCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.56
MAPT P10636 10/20 0.55
ALDH1A1 P00352 5/20 0.55
TP53 P04637 4/20 0.55
MAPK1 P28482 4/20 0.55
HTT P42858 3/20 0.55
ALOX15 P16050 3/20 0.55
KDM4E B2RXH2 3/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
USP2 O75604 2/20 0.55
HSD17B10 Q99714 1/20 0.55
RAB9A P51151 5/20 0.54
NPC1 O15118 4/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
PLK4 O00444 1/20 0.53
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
ALOX12 P18054 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28349769 0.98 GAA (0.54) GAAMAPTALDH1A1TP53MAPK1
SCHEMBL14752400 0.90 GAA (0.47) GAAMAPTALDH1A1TP53MAPK1
SCHEMBL3829986 0.87 MAPT (0.59) MAPTALDH1A1TP53MAPK1KDM4E
SCHEMBL22198281 0.85 ALDH1A1 (0.57) GAAMAPTALDH1A1TP53MAPK1
SCHEMBL7066138 0.83 LMNA (0.56) GAAMAPTALDH1A1TP53MAPK1
SCHEMBL7980595 0.83 MAPT (0.62) GAAMAPTALDH1A1TP53MAPK1
SCHEMBL2174874 0.83 MAPT (0.58) GAAMAPTALDH1A1TP53MAPK1
SCHEMBL17361558 0.83 MAPT (0.53) GAAMAPTALDH1A1TP53MAPK1
SCHEMBL22025442 0.82 KDM4E (0.50) GAAMAPTALDH1A1TP53MAPK1
SCHEMBL9093746 0.82 LMNA (0.71) MAPTALDH1A1TP53MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109678852-A 6- oxo hexahydropyrimidine derivative, preparation method and pharmacy application 南京中医药大学 2019-04-26 CN claimed
US-20250066355-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2025-02-27 US disclosed
US-12172998-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-12-24 US disclosed
CN-111909083-B Inhibitors of histone demethylase 赛尔基因昆蒂赛尔研究公司 2023-08-15 CN disclosed
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 US disclosed
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-04-20 US disclosed
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-04-20 US disclosed
US-11535616-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC (US) 2022-12-27 US disclosed
US-11535616-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC (US) 2022-12-27 US disclosed
CN-115484953-A Methods of treating cytokine storm syndrome and related diseases 健艾仕生物医药有限公司 2022-12-16 CN disclosed
EP-1237867-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS Darwin Discovery Limited (GB) 2002-09-11 EP disclosed
EP-0754176-B1 NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE VERTEX PHARMA (US) 2001-12-05 EP disclosed
EP-1138673-A2 Novel carbamates and ureas as modifiers of multi-drug resistance Vertex Pharmaceuticals Incorporated (US) 2001-10-04 EP disclosed
WO-2001044188-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS DARWIN DISCOVERY LIMITED (GB) 2001-06-21 WO disclosed
EP-0941113-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS Vertex Pharmaceuticals Incorporated (US) 1999-09-15 EP disclosed
US-5780484-A Methods for stimulating neurite growth with piperidine compounds VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-07-14 US disclosed
WO-1998020893-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-05-22 WO disclosed
US-5744485-A INCREASE SENSITIVITY OF CELLS; CANCER VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-04-28 US disclosed
EP-0754176-A1 NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE Vertex Pharmaceuticals Incorporated (US) 1997-01-22 EP disclosed
WO-1995026337-A1 NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE VERTEX PHARMACEUTICALS INCORPORATED (US) 1995-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12172998-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5C GAA 1975/4885MAPT 2716/4885ALDH1A1 392/4885
US-11535616-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5C GAA 1975/4885MAPT 2716/4885ALDH1A1 392/4885
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C GAA 1975/4885MAPT 2716/4885ALDH1A1 392/4885
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 GAA 4095/4885MAPT 326/4885ALDH1A1 2647/4885
US-20250066355-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C GAA 1975/4885MAPT 2716/4885ALDH1A1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.